Coronavirus 2019 Disease (COVID-19), Systemic Inflammation, and Cardiovascular Disease.
Coronavirus 2019 Disease (COVID-19), Systemic Inflammation, and Cardiovascular Disease.
复制标题
DOI：
10.1161/jaha.120.017756
复制
发表时间：
2020-08-18
影响因子：
5.4
通讯作者：
Metra M
中科院分区：
文献类型：
--
作者：
Inciardi RM;Solomon SD;Ridker PM;Metra M
（SARS-CoV-2）已在全球范围内迅速蔓延，并对公共卫生和医学界提出了严峻的挑战。世界卫生组织已宣布SARS-CoV-2为国际关注的突发公共卫生事件，截至2020年6月12日，全球估计有超过700万人感染，超过40万人死亡。1中国2019冠状病毒病（COVID-19）医疗救治专家组2020年的一份报告2显示，病毒感染的临床谱以发热（住院期间高达88. 7%的患者）和咳嗽（67. 8%的患者）为主，其次是头痛、疲劳或呼吸急促等症状。肺功能的迅速恶化与肺炎的严重程度不成比例，表明细胞因子风暴是COVID-19感染的主要危及生命的并发症。迄今为止，除了抗生素治疗和呼吸机支持外，没有药物治疗在COVID-19患者中显示出明显的益处。然而，了解感染并发症的潜在机制至关重要。
(SARS-CoV-2), has rapidly spread worldwide and presents critical challenges for the public health and medical communities. The World Health Organization has declared SARS-CoV-2 a public health emergency of international concern, with a global estimate of over 7 million human infections and more than 400 000 deaths worldwide as of June 12, 2020. 1 A 2020 report by the China Medical Treatment Expert Group for Coronavirus Disease 2019 (COVID-19) 2 showed that the clinical spectrum of the viral infection is dominated by fever (up to 88.7% of patients during hospitalization) and cough (67.8% of patients), followed by symptoms such as headache, fatigue, or shortness of breath. Rapid deterioration of lung function, disproportionate to the magnitude of pneumonia, has implicated the cytokine storm as a major life-threatening complication of COVID-19 infection. To date, other than antibiotic therapy and ventilator support, no drug therapies have shown clear benefit in patients with COVID-19. Nevertheless, understanding the mechanisms underlying the complications from the infection is critical.